Adenoviral delivery of human CDC5 promotes G2/M progression and cell division in neonatal ventricular cardiomyocytes.
Heart failure results from the cumulative death of cardiomyocytes, and the inability of remaining cells to regenerate. Efforts toward transcriptional reprogramming of cardiomyocytes by overexpressing E1A or E2F1 have been limited by the inability of cardiomyocytes to enter and complete mitosis. Human CDC5 (hCDC5), a component of the pre-mRNA splicing complex, has been shown to regulate G2/M transit in asynchronously dividing cells. We now show that co-infection of recombinant adenoviruses expressing E1A/E1B and hCDC5 promotes cell cycle re-entry and G2/M progression in post-mitotic cardiomyocytes. Co-expression of E1A/E1B and hCDC5 induced nuclear localization of cyclin-dependent kinase 1 and cyclin B1, and was sufficient to promote mitotic entry as determined by an increase in mitotic index only in co-infected cells. E1A/E1B and hCDC5 promoted cell division, as evidenced by an increase in the number of cardiomyocytes following co-infection. Thus, overexpression of E1A/E1B and hCDC5 resulted in cell cycle re-entry, DNA synthesis, cell division, and an increase in cardiomyocyte number, suggesting the formation of new cardiomyocytes. These studies suggest that G1/S-phase transcriptional regulators, in combination with pre-mRNA splicing factors, such as CDC5, that regulate rate-limiting G2/M target genes may prove useful in developing therapies to stimulate myocardial regeneration.
Cardiovascular Research Institute, University of California, San Francisco, CA 92121, USA.
S D
SD
Williams
H
H
Zhu
L
L
Zhang
H S
HS
Bernstein
D000256:Adenoviridae / Q000235:genetics*; D017500:Adenovirus E1A Proteins / Q000235:genetics; D017501:Adenovirus E1B Proteins / Q000235:genetics; D002452:Cell Count; D018797:Cell Cycle Proteins / Q000235:genetics*; D002455:Cell Division; D004247:DNA / Q000096:biosynthesis; D050687:E2F1 Transcription Factor / Q000235:genetics; D016195:G2 Phase; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D007231:Infant, Newborn; D032383:Myocytes, Cardiac / Q000166:cytology*; D011401:Promoter Regions, Genetic; D014158:Transcription, Genetic
D017500:Adenovirus E1A Proteins; D017501:Adenovirus E1B Proteins; D018797:Cell Cycle Proteins; D050687:E2F1 Transcription Factor; D004247:DNA